Group 1 - The core point of the article is that Suosheng Biotechnology has received a medical device registration certificate from the National Medical Products Administration for products including the "Adenovirus Antigen Test Kit (Colloidal Gold Method)" [1] - For the fiscal year 2024, Suosheng Biotechnology's revenue composition is 94.78% from the in vitro diagnostic industry and 5.22% from other businesses [1] - As of the report, Suosheng Biotechnology has a market capitalization of 5.4 billion yuan [1] Group 2 - The article also highlights a competitive situation in the beverage industry, where Nongfu Spring's new green bottle product has led to a significant decline in market share for Yibao, dropping nearly 5 percentage points [1]